脑性瘫痪治疗后肌肉协同仅出现极小变化
该研究评估了147名脑性瘫痪(CP)儿童在接受A型肉毒毒素注射、选择性脊神经后根切断术或多平面骨科手术前后的肌肉协同。结果显示,尽管步态模式发生改变,肌肉协同的复杂性、权重和激活模式在治疗后仅有极小变化,且仅协同激活模式的变化与步态结局相关。
要点
- 三种常见治疗后,所需协同数量无显著变化,协同权重亦无变化。
- A型肉毒毒素注射和选择性脊神经后根切断术后,单一协同解释的总方差略有增加。
- 仅协同激活模式的变化与步态运动学或步行速度的改善相关。
核心结论
- 脑性瘫痪儿童接受三种常见治疗后,肌肉协同仅出现极小变化,提示神经肌肉控制难以通过现有治疗改变。
研究设计与样本
- 研究纳入147名脑性瘫痪儿童,分别在A型肉毒毒素注射(n=52)、选择性脊神经后根切断术(n=38)和多平面骨科手术(n=57)前后评估肌肉协同,并与31名典型发育同伴的平均协同进行比较。
主要发现
- 任何治疗组的协同数量均无显著变化。
- A型肉毒毒素注射后单一协同解释的总方差增加1.3%,选择性脊神经后根切断术后增加1.9%,变化均较小。
- 任何治疗组的协同权重均无变化(平均变化0.001 ± 0.10)。
- 选择性脊神经后根切断术后协同激活模式发生变化,与典型发育同伴的相似性降低(-0.03 ± 0.07)。
- 仅协同激活模式的变化与步态运动学或步行速度的变化相关;治疗后协同激活模式更接近典型发育同伴的儿童步态改善更大。
关键数值与推荐
- 协同复杂性以解释肌电数据总方差>90%所需的协同数量及单一协同解释的总方差来衡量。
- 协同权重和激活模式通过相对于31名典型发育同伴平均协同的余弦相似度进行比较。
临床怎么用
- 现有治疗虽可改变步态模式,但难以改变脑性瘫痪儿童的神经肌肉协同控制策略。
- 治疗后协同激活模式更接近典型发育同伴的儿童步态改善更大,提示可关注协同激活模式的变化。
- 可能需要开发直接针对受损控制或根据个体独特控制模式优化的治疗策略来改善步行功能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Children with cerebral palsy (CP) have altered synergies compared to typically-developing peers, reflecting different neuromuscular control strategies used to move. While these children receive a variety of treatments to improve gait, whether synergies change after treatment, or are associated with treatment outcomes, remains unknown. METHODS: We evaluated synergies for 147 children with CP before and after three common treatments: botulinum toxin type-A injection (n = 52), selective dorsal rhizotomy (n = 38), and multi-level orthopaedic surgery (n = 57). Changes in synergy complexity were measured by the number of synergies required to explain > 90% of the total variance in electromyography data and total variance accounted for by one synergy. Synergy weights and activations before and after treatment were compared using the cosine similarity relative to average synergies of 31 typically-developing (TD) peers. RESULTS: There were minimal changes in synergies after treatment despite changes in walking patterns. Number of synergies did not change significantly for any treatment group. Total variance accounted for by one synergy increased (i.e., moved further from TD peers) after botulinum toxin type-A injection (1.3%) and selective dorsal rhizotomy (1.9%), but the change was small. Synergy weights did not change for any treatment group (average 0.001 ± 0.10), but synergy activations after selective dorsal rhizotomy did change and were less similar to TD peers (- 0.03 ± 0.07). Only changes in synergy activations were associated with changes in gait kinematics or walking speed after treatment. Children with synergy activations more similar to TD peers after treatment had greater improvements in gait. CONCLUSIONS: While many of these children received significant surgical procedures and prolonged rehabilitation, the minimal changes in synergies after treatment highlight the challenges in altering neuromuscular control in CP. Development of treatment strategies that directly target impaired control or are optimized to an individual's unique control may be required to improve walking function.
引用
- Shuman BR, Goudriaan M, Desloovere K, et al. Muscle synergies demonstrate only minimal changes after treatment in cerebral palsy. J Neuroeng Rehabil. 2019. PMID: 30925882. doi:10.1186/s12984-019-0502-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。